Background
Spontaneous tropism changes (from R5 to non-R5 or vice-versa) were observed in approximately 10% of patients between screening and study baseline in the maraviroc (MVC) clinical trials. Little is known of the biology of these apparent short-term tropism fluctuations.
Methods
Population-based and "deep" V3-loop sequencing were performed in 53 MVC recipients in the MERIT, MOTIVATE and A4001029 studies who spontaneously changed tropism readout by the original Trofile assay between screening and baseline (~4-8 weeks) and 72 randomly sampled patients who did not change. Tropism was inferred by "geno2pheno" with previously defined cutoffs: 2% X4 prevalence with a 3.5% false-positive rate (fpr) for "deep" sequencing; 5.75% fpr for population-based sequencing.
Results
Patients changing Trofile readout from R5 to non-R5 had significantly higher screening non-R5 prevalence by "deep" sequencing than those who remained R5, and this increased slightly by the baseline timepoint (Table
1). Similarly, patients who changed tropism from non-R5 to R5 in the A4001029 trial had a lower percentage of non-R5 viruses at screening and baseline. Although there was no difference in total viral load, absolute CXCR4-using plasma virus load was higher in those who changed tropism at screening (2.7 vs. 0 log
10 copies/mL, p=0.02 in MERIT; 3.1 vs. 0 log
10 copies/mL, p<0.0001 in MOTIVATE) and baseline (3.0 vs. 0 log
10 copies/mL, p=0.04 in MERIT; 3.8 vs. 0 log
10 copies/mL, p<0.0001 in MOTIVATE). Non-R5 was reported at screening in 26% and 49% of patients who changed phenotype to non-R5 by population and deep-sequencing, respectively.
MERIT | 25 | 13 | 0 [0-0] | 1.9 [0-3.3] | 0.01 | 0 [0-0.1] | 7 [0-16.3] | 0.04 |
MOTIVATE | 25 | 32 | 0 [0-0.1] | 2.4 [0.1-21.3] | 0.0001 | 0 [0-0.1] | 9.1 [0.4-32.7] | <0.0001 |
A4001029 | 22 | 8 | 5.0 [0.2-91.5] | 1.8 [0.4-30.6] | 0.5 | 4.3 [0-76.6] | 0.4 [0-47.5] | 0.3 |
Conclusions
In most cases, the prevalence of non-CCR5 usage inferred from "deep" sequencing was stable over the short term between screening and baseline. Where apparent phenotypic tropism changes from R5 to non-R5 occurred, non-R5 virus was generally detectable at the screening timepoint by genotype, coupled with relatively small increases in non-R5 virus by baseline. Small variations in CXCR4-using HIV populations around the phenotypic assay detection limit, rather than coreceptor switch, contributed to apparent tropism switching from R5 to non-R5.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (
http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.